Diacerein
A slow-acting drug of natural origin that modulates interleukin-1 and promotes cartilage repair. Used in osteoarthritis treatment with anti-inflammatory effects.
Research Status
Clinical trials
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Occurs in 10-30% of users, typically mild and self-limiting. Usually resolves within 1-2 weeks. Taking diacerein with food significantly reduces incidence. If severe, dose reduction or temporary discontinuation may be needed.
Expected and harmless. Results from the drug's metabolite (rhein) being excreted in urine. No clinical significance; reassure patients this is normal.
Occurs in 5-10% of users. Usually mild and associated with GI upset. Taking with food helps prevent. Discontinue if severe.
Reported in 3-8% of users. Taking with food reduces incidence. Typically resolves with continued use.
Less common than diarrhea but reported in some users. Ensure adequate hydration and fiber intake. May alternate with diarrhea in some patients.
Skin reactions reported in <1% of users. Usually mild and self-resolving. Discontinue if severe or accompanied by systemic symptoms.
Very rare but documented. Elevated liver enzymes reported in <0.1% of users. Monitor liver function tests (ALT, AST) at baseline and periodically during treatment, especially in patients with pre-existing liver disease. Discontinue immediately if jaundice or signs of liver injury develop.
Rare but reported, particularly in patients with pre-existing renal disease. Diacerein is contraindicated in severe renal impairment (creatinine clearance <30 mL/min). Monitor renal function at baseline and periodically.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 50 mg |
| Frequency | 2x daily |
| Timing | With meals to reduce gastrointestinal upset |
| Route | Subcutaneous |
Standard clinical dose is 50mg twice daily. Therapeutic effects typically emerge after 2-3 months of consistent use. For research purposes only.
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2–8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
Diacerein is a slow-acting drug that inhibits interleukin-1 (IL-1) production and signaling in cartilage and synovial tissues. By suppressing IL-1-mediated inflammation and cartilage-degrading enzyme activity, diacerein reduces joint damage progression and promotes endogenous cartilage repair mechanisms. Its effects develop gradually over weeks to months, making it a disease-modifying osteoarthritis drug (DMOAD) rather than a rapid analgesic.
Interleukin-1 Inhibition
Diacerein reduces IL-1β production by synovial cells and macrophages, decreasing the inflammatory cascade that drives cartilage degradation and joint destruction in osteoarthritis.
Matrix Metalloproteinase (MMP) Suppression
By blocking IL-1 signaling, diacerein reduces expression of MMPs (particularly MMP-1, MMP-3, and MMP-13) that degrade cartilage matrix proteins.
Cartilage Repair Promotion
Diacerein enhances synthesis of cartilage matrix components including proteoglycans and collagen type II, supporting endogenous repair mechanisms.
NF-κB Pathway Modulation
Diacerein inhibits nuclear factor-kappa B (NF-κB) activation, a key transcription factor driving inflammatory gene expression in osteoarthritis.
- Diacerein is a slow-acting drug — therapeutic effects typically require 2-3 months of consistent use
- It is classified as a disease-modifying osteoarthritis drug (DMOAD), not a simple pain reliever
- IL-1 inhibition is the primary mechanism; diacerein does not directly block IL-1 receptors but reduces IL-1 production
- Efficacy is most evident in knee osteoarthritis; evidence for hip and hand OA is more limited
- Long-term use (>3 years) shows sustained benefit in slowing radiographic progression of joint damage
Track your Diacerein research
Free account. No credit card required.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Diacerein is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.